Summit Therapeutics (SMMT) Price & Analysis

Compare

1,617 Followers

SMMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.60 - $36.91

Previous CloseN/A

Volume1.23M

Average Volume (3M)3.37M

Market Cap

$21.28B

Enterprise Value$13.88B

Total Cash (Recent Filing)$361.31M

Total Debt (Recent Filing)$6.45M

Price to Earnings (P/E)―

Beta2.36

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding742,665,900

10 Day Avg. Volume2,388,085

30 Day Avg. Volume3,372,935

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.65

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-347.07K

Enterprise Value/Ebitda-59.12

Forecast

1Y Price Target

$35.38

Price Target Upside23.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Business DevelopmentIncreasing business development interest for Summit is encouraging, following the Pfizer collaboration announced earlier this year.

Partnerships And CollaborationsSummit's collaboration with Revolution Medicines is positive for ivonescimab's long-term value and highlights the value of ivo's developmental lead compared to other VEGF-A/PD-(L)1 bispecifics.

Bears Say

CompetitionSMMT faces competition from other manufacturers rapidly developing their VEGF-A/PD-(L)1 bispecific in combination regimens.

Development RisksRisks include delays in ivonescimab development, clinical trial failures, and possible medium-term dilution risk.

Market SkepticismThere is skepticism regarding whether a pharmacos would buy ivonescimab at a high price, considering other available options.

Summit Therapeutics News

Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial

Summit Therapeutics PLC (($SMMT)), Summit Therapeutics (($GB:SUMM)) announced an update on their ongoing clinical study. Summit Therapeutics PLC,...

3d ago

SMMT

3 Stocks Flashing ‘Strong Buy’ Signals, According to Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

1M ago

QXO

PSTG

Summit Therapeutics Stock (SMMT) Jumps 8% on Talks of $15B Licensing Deal with AstraZeneca

Summit Therapeutics ($SMMT) stock jumped 8.5% on Thursday in reaction to a Bloomberg report about talks between the...

1M ago

AZN

SMMT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

1M ago

AZN

RVMD

AstraZeneca discussing $15B partnership with Summit Therapeutics, Bloomberg says

AstraZeneca (AZN) is in talks regarding a potential partnership deal with Summit Therapeutics (SMMT) in which it could...

1M ago

AZN

SMMT

Summit Therapeutics up 1% after report on AstraZeneca partnership talks

10:27 EDT Summit Therapeutics (SMMT) up 1% after report on AstraZeneca (AZN) partnership talks Published first on TheFly...

1M ago

AZN

SMMT

AstraZeneca discussing $15B partnership with Summit Therapeutics, Bloomberg says

AstraZeneca (AZN) is in talks regarding a potential partnership deal with Summit Therapeutics (SMMT) in which it could...

1M ago

AZN

SMMT

Summit Therapeutics trading resumes

10:24 EDT Summit Therapeutics (SMMT) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

1M ago

SMMT

Summit Therapeutics in talks for $15B AstraZeneca partnership, Bloomberg says

10:17 EDT Summit Therapeutics (SMMT) in talks for $15B AstraZeneca (AZN) partnership, Bloomberg says Published first on TheFly...

1M ago

AZN

SMMT

Summit Therapeutics trading halted, volatility trading pause

10:19 EDT Summit Therapeutics (SMMT) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

1M ago

SMMT

Strategic Collaboration and Growth Potential Drive Positive Outlook for Summit Therapeutics

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining...

1M ago

SMMT

Summit Therapeutics initiated with a Buy at UBS

UBS initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $30 price target The firm believes...

1M ago

SMMT

Revolution Medicines, Summit Therapeutics enter clinical collaboration

Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) announced the companies have entered into a clinical collaboration in multiple...

1M ago

RVMD

SMMT

Revolution Medicines, Summit Therapeutics team to evaluate RAS inhibitors

Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) announced the companies have entered into a clinical collaboration in multiple...

1M ago

RVMD

SMMT

SMMT FAQ

What was Summit Therapeutics PLC’s price range in the past 12 months?

Summit Therapeutics PLC lowest stock price was $10.60 and its highest was $36.91 in the past 12 months.

What is Summit Therapeutics PLC’s market cap?

Summit Therapeutics PLC’s market cap is $21.28B.

When is Summit Therapeutics PLC’s upcoming earnings report date?

Summit Therapeutics PLC’s upcoming earnings report date is Nov 05, 2025 which is in 86 days.

How were Summit Therapeutics PLC’s earnings last quarter?

Currently, no data Available

Is Summit Therapeutics PLC overvalued?

According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Summit Therapeutics PLC pay dividends?

Summit Therapeutics PLC does not currently pay dividends.

What is Summit Therapeutics PLC’s EPS estimate?

Summit Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Summit Therapeutics PLC have?

Summit Therapeutics PLC has 742,665,900 shares outstanding.

What happened to Summit Therapeutics PLC’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Summit Therapeutics PLC?

Currently, no hedge funds are holding shares in SMMT

Summit Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-123.93%

Trailing 12-Months

Asset Growth

117.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Summit Therapeutics PLC

Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibiotics to combat infections caused by multi-drug resistant bacteria. The company operates in the healthcare sector, with a primary focus on developing new treatments for infectious diseases through its innovative pipeline of antibiotic candidates.

Summit Therapeutics (SMMT) Earnings & Revenues

Historic Earnings Reports

SMMT Company Deck

SMMT Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented significant positive developments, particularly the regulatory approval and promising interim results for ivonescimab, indicating strong progress in its clinical development. However, challenges such as limited market opportunities for specific trials and increased G&A expenses were noted. Overall, the positive highlights significantly outweigh the lowlights.View all SMMT earnings summaries

SMMT Stock 12 Month Forecast

Average Price Target

$35.38

▲(23.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","26":"$26","45":"$45","16.5":"$16.5","35.5":"$35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,16.5,26,35.5,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,22.953846153846154,24.707692307692305,26.46153846153846,28.215384615384615,29.96923076923077,31.723076923076924,33.47692307692307,35.230769230769226,36.98461538461538,38.738461538461536,40.49230769230769,42.246153846153845,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,22.29076923076923,23.38153846153846,24.47230769230769,25.563076923076924,26.653846153846153,27.744615384615386,28.835384615384616,29.926153846153845,31.016923076923078,32.10769230769231,33.198461538461544,34.28923076923077,{"y":35.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.2,21.876923076923077,22.553846153846152,23.23076923076923,23.907692307692308,24.584615384615383,25.26153846153846,25.93846153846154,26.615384615384613,27.29230769230769,27.96923076923077,28.646153846153844,29.323076923076922,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.14,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >